Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsOPHTHALMICStandard

CYSTARAN

CYSTEAMINE HYDROCHLORIDE

Standard Dose
EQ 0.44% BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: N/A Marketing status: Prescription
Summary

Approval overview CYSTARAN is listed in Drugs@FDA under application 200740 (NDA).

Review priority: N/A Marketing status: Prescription Active ingredient CYSTEAMINE HYDROCHLORIDE Form and strength SOLUTION/DROPS;OPHTHALMIC - EQ 0.44% BASE Sponsor LEADIANT BIOSCI INC Submission history Latest submission status date: 2022-02-25 00:00:00.

Structured Monograph

Clinical summary

Approval overview CYSTARAN is listed in Drugs@FDA under application 200740 (NDA). Review priority: N/A Marketing status: Prescription Active ingredient CYSTEAMINE HYDROCHLORIDE Form and strength SOLUTION/DROPS;OPHTHALMIC - EQ 0.44% BASE Sponsor LEADIANT BIOSCI INC Submission history Latest submission status date: 2022-02-25 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: N/A

Interaction Notes

  • No interaction notes stored yet.